Compare Ascendis Pharma A/S (ASND) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs IAC/Interactivecorp — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while IAC/Interactivecorp trades at $40.21 (market cap $3.03B). The key difference: Ascendis Pharma A/S is far larger — about 5.5× IAC/Interactivecorp's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, IAC/Interactivecorp nearer its low. Which is the better fit depends on your goals.
| ASND | PPLI | |
|---|---|---|
Market Cap | $16.78B | $3.03B |
Sector | Health | Media |
52-Week High | $277.18 | $47.62 |
52-Week Low | $189.74 | $31.52 |
Enterprise Value | $17.15B | $3.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.
ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.
People Incorporated (PPLI) trades at $41.58, down 3.17% amid bearish technical signals despite strong Q2 2026 earnings beat. The company shows mixed fundamentals with attractive valuation ratios (P/E 7.04, P/B 0.61) but volatile profitability trends. Recent news highlights digital revenue growth, corporate restructuring, and MGM investment gains, while institutional activity shows mixed positioning with Amundi increasing stake by 397.4% in Q2 2026.
PPLI presents a value opportunity with deep discount to analyst consensus target of $60.50 (45% upside), though investors face execution risks from restructuring and inconsistent earnings history. The stock's near-term direction hinges on successful asset monetization and sustained digital growth against backdrop of negative cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
